LncRNA CDKN2B-AS1 Could Be an Indicator to Identify Prognosis and Status of Immune Microenvironment in Thyroid Cancer. (8th April 2022)

• Record Type: Journal Article
• Authors: Xue, Cheng; Yi, Cheng; Lin, Haiyang; Zhao, Jiajia; Yuan, Junhui; Chen, Yongzheng; Chen, Haibing; Lin, Li; Zhao, Yisha
• Other Names: Wang Fu Academic Editor.
• Is Part Of: Disease markers. Volume 2022(2022)
• Publication Date: 2022-04-08
• Subjects: Diagnosis -- Periodicals; Biochemical markers -- Periodicals; Pathology -- Periodicals; 616
• DOI: 10.1155/2022/4317480
• Languages: English
• ISSNs: 0278-0240

Abstract

Abstract : Thyroid cancer (TC) is prone to recurrence, and biomarkers for predicting progression-free interval (PFI) are poorly explored. The study investigates the predictive value and underlying biological mechanisms of lncRNA CDKN2B-AS1 in TC. Combining RNA-seq and survival data, we identified that CDKN2B-AS1 was upregulated in TC samples and could be an excellent prognostic indicator. To exclude confounding factors, we divided patients into different subgroups using median CDKN2B-AS1 expression, and the effects of CDKN2B-AS1 on PFI and clinical features were explored in different clinical subgroups. Meanwhile, ssGSEA and ESTIMATE algorithms revealed that CDKN2B-AS1 overexpression may suggest the active state of the immune microenvironment. On the other hand, enrichment analysis also proved the potential influence of CDKN2B-AS1 on immune regulation in TC. Finally, we created a CDKN2B-AS1, microRNAs, and TFs network and discovered a new biomarker (CDKN2B-AS1) that might be employed as a therapeutic target in TC patients.